ScoreWhy is Fuan Pharmaceutical (Group) Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 2.09%
- The company has been able to generate a Return on Capital Employed (avg) of 2.09% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -7.28% and Operating profit at -188.72% over the last 5 years
3
The company has declared Negative results for the last 6 consecutive quarters
- NET PROFIT(HY) At CNY -32.21 MM has Grown at -140.28%
- INTEREST(HY) At CNY 8.99 MM has Grown at 25.45%
- NET SALES(9M) At CNY 1,225.28 MM has Grown at -14.08%
4
Below par performance in long term as well as near term
- Along with generating -17.08% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Fuan Pharmaceutical (Group) Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Fuan Pharmaceutical (Group) Co., Ltd. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Fuan Pharmaceutical (Group) Co., Ltd.
-12.13%
-0.15
26.70%
China Shanghai Composite
0.9%
1.20
14.07%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-7.28%
EBIT Growth (5y)
-188.72%
EBIT to Interest (avg)
-4.51
Debt to EBITDA (avg)
0.18
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.42
Tax Ratio
12.51%
Dividend Payout Ratio
108.19%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.26%
ROE (avg)
4.59%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
62
Industry P/E
Price to Book Value
0.90
EV to EBIT
-40.76
EV to EBITDA
59.71
EV to Capital Employed
0.89
EV to Sales
2.24
PEG Ratio
NA
Dividend Yield
2.10%
ROCE (Latest)
-2.19%
ROE (Latest)
1.45%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
NET PROFIT(Q)
At CNY 40.76 MM has Grown at 152.25%
RAW MATERIAL COST(Y)
Fallen by -22.25% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -4.62 %
OPERATING PROFIT(Q)
Highest at CNY 96.69 MM
OPERATING PROFIT MARGIN(Q)
Highest at 22.39 %
PRE-TAX PROFIT(Q)
Highest at CNY 48.44 MM
-6What is not working for the Company
NET PROFIT(9M)
At CNY 8.55 MM has Grown at -93.09%
ROCE(HY)
Lowest at 1.35%
Here's what is working for Fuan Pharmaceutical (Group) Co., Ltd.
Pre-Tax Profit
At CNY 48.44 MM has Grown at 446.58%
over average net sales of the previous four periods of CNY -13.98 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 40.76 MM has Grown at 152.25%
over average net sales of the previous four periods of CNY 16.16 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Operating Profit
Highest at CNY 96.69 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 22.39 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 48.44 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Debt-Equity Ratio
Lowest at -4.62 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -22.25% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
